Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €27.90 EUR
Change Today +0.053 / 0.19%
Volume 100.0
ER4 On Other Exchanges
Symbol
Exchange
Berlin
New York
As of 3:21 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

emergent biosolutions inc (ER4) Snapshot

Open
€27.97
Previous Close
€27.85
Day High
€28.20
Day Low
€27.40
52 Week High
04/14/15 - €28.60
52 Week Low
10/13/14 - €15.22
Market Cap
1.1B
Average Volume 10 Days
137.0
EPS TTM
--
Shares Outstanding
38.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EMERGENT BIOSOLUTIONS INC (ER4)

emergent biosolutions inc (ER4) Related Businessweek News

No Related Businessweek News Found

emergent biosolutions inc (ER4) Details

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body’s immune system. The company’s biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent’s commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, which was founded in 1998, is based in Rockville, Maryland.

1,280 Employees
Last Reported Date: 03/9/15
Founded in 1998

emergent biosolutions inc (ER4) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $1.2M
Founder, Executive Chairman, Chairman of Stra...
Total Annual Compensation: $881.5K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $659.5K
Executive Vice President and President of Bio...
Total Annual Compensation: $623.1K
Executive Vice President and President of Bio...
Total Annual Compensation: $558.7K
Compensation as of Fiscal Year 2014.

emergent biosolutions inc (ER4) Key Developments

Emergent BioSolutions Inc. Enters into Long-Term Manufacturing Agreement with ProMetic Life Sciences Inc

Emergent BioSolutions Inc. announced that it has signed a strategic long-term manufacturing agreement with ProMetic Life Sciences Inc. This agreement provides ProMetic access to Emergent's cGMP FDA-licensed biopharmaceuticals facility located in Winnipeg, Manitoba, Canada. ProMetic will commence transferring its technology and manufacturing process into Emergent's Winnipeg facility as soon as possible, followed by the scale-up and manufacture by Emergent of cGMP biopharmaceuticals to enable ProMetic to pursue additional IND filings. Under the terms of this manufacturing agreement, ProMetic is obligated to purchase at least CAD 4 million of capacity in the first full contract year. The minimum order amount increases over the 15-year life of the contract. The aggregate total of the minimum fees over the life of the contract is in excess of CAD 100 million. The agreement also provides flexibility to the parties in the event services in excess of the minimum are requested by ProMetic. These services will be charged on an as-used basis.

Emergent BioSolutions, Inc. - Shareholder/Analyst Call

Annual Meeting of Stockholders

Emergent BioSolutions, Inc. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter of 2015; Reaffirms Earnings Guidance for the Full Year 2015

Emergent BioSolutions, Inc. reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $63,633,000 compared with $53,884,000 for the same period last year. Loss from operations was $28,310,000 compared with $25,458,000 for the same period last year. Loss before benefit from income taxes was $29,789,000 compared with $28,441,000 for the same period last year. Net loss was $21,520,000 or $0.57 diluted per share compared with $20,236,000 or $0.55 diluted per share for the same period last year. Net cash used in operating activities was $65,873,000 compared with $29,245,000 for the same period last year. Purchases of property, plant and equipment was $9,082,000 compared with $4,590,000 for the same period last year. EBITDA was $19.6 million, or $0.52 per diluted share, as compared to $18.1 million, or $0.49 per diluted share, in 2014. Adjusted EBITDA was $18.4 million, or $0.48 per diluted share, as compared to $13.5 million or $0.37 per diluted share, in 2014. Adjusted net loss was $18.8 million, or $0.50 per diluted share, as compared to an adjusted net loss of $14.6 million, or $0.40 per diluted share, in 2014. For the second quarter of 2015 total revenues is expected to be of $105 million to $120 million. For full year 2015, the company reaffirming forecast for total revenues of between $510 million and $540 million for the year, including between $270 million and $285 million of BioThrax product sales, and net income between $50 million and $60 million on a GAAP basis and between $60 million and $70 million on an adjusted basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ER4:GR €27.90 EUR +0.053

ER4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $19.74 USD -0.03
Chimerix Inc $42.47 USD -0.42
Depomed Inc $20.59 USD -0.17
Nektar Therapeutics $11.53 USD -0.34
Skyepharma PLC 295.00 GBp +4.00
View Industry Companies
 

Industry Analysis

ER4

Industry Average

Valuation ER4 Industry Range
Price/Earnings 40.0x
Price/Sales 2.5x
Price/Book 2.2x
Price/Cash Flow 33.3x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit www.emergentbiosolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.